Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients

Abstract

Adult patients with haematological malignancies (HM) and coronavirus disease 2019 (COVID-19) have a higher mortality than healthy subjects. [1][2][3] In particular, haematopoietic stem-cell transplantation (HSCT) recipients have a poor prognosis, 4,5 strongly supporting the role of vaccination. Patients with HM also show an attenuated immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection, 6 predicting a low rate of seroconversion after vaccination, as confirmed in several recent studies, particularly in B cell malignancies. 7-13 However, autologous or allogeneic HSCT recipients were reported to have the highest numerical responses. 7